Latest / Stock Movers / Eli Lilly Drug Test Result; AbbVie Beat; WBD Layoffs
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The Stock Movers Report,
- 0:10Speaker 1: your roundup of companies making moves in the stock market,
- 0:13Speaker 1: harnessing the power of Bloomberg data. Stock movers, I don't
- 0:18Speaker 1: know is it all tech today?
- 0:20Speaker 2: Stock nos not doing tech. I'll start with this trial
- 0:24Speaker 2: that we're just learning about of Eli. Lily's blockbuster diabetes drug,
- 0:29Speaker 2: manjuro fell short of expectations that it could do a
- 0:32Speaker 2: better job of preventing heart attacks and strokes than its
- 0:35Speaker 2: older medicine that we know is Trulicity. So they had
- 0:38Speaker 2: a head to head study of the two treatments. Lily's
- 0:41Speaker 2: largest and longest of injar to date was designed to
- 0:44Speaker 2: prove what's called non inferiority that manjuro was an acceptable
- 0:50Speaker 2: alternative when it comes to reducing risk from cardiovascular events
- 0:54Speaker 2: compared with Trillicity well at achieve that target. The study
- 0:57Speaker 2: dashed investors' hopes that majuro w be meaningfully better than
- 1:02Speaker 2: its old drug. More than thirteen thousand people with type
- 1:05Speaker 2: two diabetes and a history of heart disease enrolled in
- 1:08Speaker 2: this trial, during which they were treated with either Manjurro
- 1:12Speaker 2: or Trillicity, followed for an average of about four years,
- 1:16Speaker 2: So kind of disappointing for Lily this morning. And then
- 1:20Speaker 2: I'll move on to another drug maker, AVV ticker symbl ABBV,
- 1:25Speaker 2: raising its full year profit forecast and you can thank
- 1:28Speaker 2: booming sales from a pair of newer immunology drugs that
- 1:32Speaker 2: beat Wall Street estimates. The company which actually based in
- 1:36Speaker 2: I didn't know this, North Chicago, Illinois. They beat forecasts
- 1:39Speaker 2: on both profit and revenue in the second quarter quarterly
- 1:42Speaker 2: sales of fifteen point four to two billion dollars adjusted
- 1:46Speaker 2: earnings of the period to ninety seven a share. That's
- 1:49Speaker 2: a twelve percent increase. It also topped expectations. Abby is
- 1:54Speaker 2: something of a bright spot in the pharmaceutical sector this year.
- 1:57Speaker 2: They've navigated the expiration the patents on its blockbuster hume Era,
- 2:03Speaker 2: which treats, among other things, ulterative colitis and Crohn's disease.
- 2:10Speaker 2: They've also avoided some of the challenges their peers have
- 2:13Speaker 2: faced with Robert F. Kennedy, including his push to try
- 2:18Speaker 2: and scrutinize vaccines. Yeah one, Mark, let's go job cuts,
- 2:23Speaker 2: Warner Brothers Motion Picture Group enacting a round of layoffs.
- 2:27Speaker 2: They're going to see job cuts across the marketing, production, strategy, operations,
- 2:31Speaker 2: and theater Ventures division. That's roughly ten percent of the
- 2:35Speaker 2: studio's workforce going to be impacted. This is according to Variety.
- 2:40Speaker 2: The move comes as Warner Brothers Discovery, the parent is
- 2:43Speaker 2: preparing to split itself in two. So the new publicly
- 2:46Speaker 2: traded company is going to be Warner Brothers, which will
- 2:49Speaker 2: include the film division as well as the TV studios
- 2:52Speaker 2: and streaming operations, and then Discovery Global that's going to
- 2:55Speaker 2: become prized of the TV networks, Discovery Plus and some
- 2:59Speaker 2: of the acids.
- 3:02Speaker 1: The Stockmovers Report from Bloomberg Radio. Check back with us
- 3:06Speaker 1: throughout the day for the latest roundup of companies making
- 3:09Speaker 1: news on Wall Street and for the latest market moving headlines.
- 3:13Speaker 1: Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg
- 3:17Speaker 1: dot com, and on Applecarplay and Android Auto with the
- 3:20Speaker 1: Bloomberg Business app.